The estimated Net Worth of Josef Schoell is at least $179 Thousand dollars as of 26 July 2017. Josef Schoell owns over 4,000 units of Cara Therapeutics Inc stock worth over $14,500 and over the last 11 years Josef sold CARA stock worth over $164,400.
Josef has made over 6 trades of the Cara Therapeutics Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently Josef exercised 4,000 units of CARA stock worth $9,000 on 26 July 2017.
The largest trade Josef's ever made was exercising 40,000 units of Cara Therapeutics Inc stock on 14 August 2014 worth over $10,000. On average, Josef trades about 7,545 units every 98 days since 2014. As of 26 July 2017 Josef still owns at least 50,000 units of Cara Therapeutics Inc stock.
You can see the complete history of Josef Schoell stock trades at the bottom of the page.
Josef's mailing address filed with the SEC is 9th, 107 Elm St, Stamford, CT 06902, USA.
Over the last 11 years, insiders at Cara Therapeutics Inc have traded over $25,200,591 worth of Cara Therapeutics Inc stock and bought 1,874,453 units worth $19,406,983 . The most active insiders traders include Edward Hurwitz, Martin Vogelbaum, and Ventures Vi Lprmv Vi, L.L.C.... On average, Cara Therapeutics Inc executives and independent directors trade stock every 19 days with the average trade being worth of $5,343. The most recent stock trade was executed by Christopher Posner on 1 August 2024, trading 4,149 units of CARA stock currently worth $1,452.
cara therapeutics is an emerging biotechnology company focused on developing novel therapeutics to treat pain, inflammation and pruritus. cara possesses both near-term clinical development opportunities combined with proprietary approaches to developing first-in-class novel therapeutics. cara's most advanced patented compound, cr845, is currently undergoing clinical testing for acute pain and uremic pruritus. this compound possesses analgesic, anti-inflammatory and antipruritic activities appropriate for multiple therapeutic applications. in addition, cara aims to develop a future pipeline of first-in-class molecules at novel analgesic and anti-inflammatory targets using its proprietary drug screening technology.
Cara Therapeutics Inc executives and other stock owners filed with the SEC include: